These studies provide strong preliminary evidence for the use of second-generation PET imaging agents targeting PSMA in the detection of metastatic PCa, and further support the important value of PET imaging targeting PSMA in PCa. This evidence concerns the gene FOLH1 and posterior cortical atrophy.